A polypeptide with anti-caries performance, polypeptide self-assembly hydrogel and its application

By developing polypeptide A3 with anti-carious properties and its self-assembled hydrogel, the impact of traditional antibacterial agents on oral bacterial balance and drug delivery problems have been solved, and effective inhibition of mutant streptococci and sustained release of dental caries sites have been achieved. Treatment provides a new caries prevention and treatment plan.

CN118561964BActive Publication Date: 2024-11-15INNOVA PEPPLUS BIOTECH LLP
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202410817799.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-24
Publication Date
2024-11-15
Estimated Expiration
2044-06-24

AI Technical Summary

Technical Problem

Traditional antibacterial agents have an adverse effect on oral bacterial balance when controlling the growth of mutant Streptococcus, and it is difficult to reach the crown site by systematic medication, and local drug delivery is difficult.

Method used

A polypeptide A3 with anti-carious properties and its self-assembled hydrogel are developed, which is formed by self-assembly in PBS buffer to maintain antibacterial activity and biocompatible, so as to achieve adhesion and sustained release of dental caries sites.

Benefits of technology

Polypeptide A3 has excellent antibacterial activity against Streptococcus mutation. Self-assembled hydrogels slowly release drugs in an acidic environment, effectively inhibiting early caries and providing a new clinical prevention and treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118561964B_ABST
    Figure CN118561964B_ABST
Patent Text Reader

Abstract

The present invention provides a polypeptide with anti-caries performance, belonging to the field of biochemical technology, and the amino acid sequence of the polypeptide is shown in SEQ ID NO.1. The polypeptide has excellent antibacterial activity against Streptococcus mutans, providing a new option for the prevention and treatment of early dental caries in clinic. The present invention also provides a polypeptide self-assembled hydrogel with anti-caries performance and its application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biochemistry, and particularly relates to a polypeptide with anti-caries performance, a polypeptide self-assembly hydrogel and applications thereof. Background Art

[0002] Antimicrobial peptides are a large class of active peptides that have resistance functions to harmful organisms (or pathogens) such as bacteria, fungi, parasites and viruses. Because they generally carry sufficient positive charges and are often accompanied by hydrophobicity, they can bind to negatively charged biofilms under electrostatic action, penetrate and destroy the membrane structure to cause cell death. Unlike the single-target bactericidal principle of traditional antibiotics, antimicrobial peptides can carry out multi-target destruction on pathogens, which can greatly reduce the production of drug-resistant bacteria and have broad-spectrum antibacterial properties. They are one of the best choices for replacing antibiotics in the future. In recent years, research on the application of antimicrobial peptides in the oral cavity has been widely carried out around the world. In the past decade, research on the control of oral pathogens by antimicrobial peptides has made a major leap. So far, many natural or synthetic antimicrobial peptides have shown inhibitory effects on the growth of Streptococcus mutans, planktonic bacteria and biofilms in vitro. They prevent and treat dental caries by inhibiting the growth of microorganisms such as Streptococcus mutans, reducing bacterial acid resistance, inhibiting microbial acid production, inhibiting biofilm formation and promoting remineralization. These studies have shown that antimicrobial peptides have the potential to become a safe and promising solution for dental caries. Summary of the invention

[0003] In order to obtain a new mutans streptococcus antimicrobial peptide, the present invention provides a polypeptide with anti-caries performance, which has excellent antibacterial activity against mutans streptococci and provides a new option for the prevention and treatment of early dental caries in clinical practice.

[0004] The invention also provides a polypeptide self-assembly hydrogel with anti-caries performance and application thereof.

[0005] The present invention is achieved through the following technical solutions:

[0006] The present invention provides a polypeptide with anti-caries performance, and the amino acid sequence of the polypeptide is shown as SEQ ID NO.1.

[0007] Based on the same inventive concept, the present invention provides a polypeptide self-assembled hydrogel with anti-caries performance, wherein the polypeptide self-assembled hydrogel contains the above-mentioned polypeptide with anti-caries performance.

[0008] Furthermore, the polypeptide self-assembly hydrogel is formed by self-assembly of the polypeptide in a solvent.

[0009] Optionally, the solvent is PBS buffer.

[0010] Based on the same inventive concept, the present invention provides an application of a polypeptide having anticaries properties in the preparation of anticaries drugs.

[0011] Based on the same inventive concept, the present invention provides an application of a polypeptide self-assembled hydrogel with anti-caries performance in the preparation of an anti-caries drug.

[0012] Based on the same inventive concept, the present invention provides an anti-caries drug, wherein the active ingredient of the anti-caries drug includes the above-mentioned polypeptide with anti-caries performance and / or a polypeptide self-assembled hydrogel with anti-caries performance.

[0013] Based on the same inventive concept, the present invention provides an application of a polypeptide having anticaries properties in inhibiting or killing Streptococcus mutans.

[0014] Based on the same inventive concept, the present invention provides an application of a polypeptide self-assembled hydrogel with anti-caries performance in inhibiting or killing Streptococcus mutans.

[0015] Based on the same inventive concept, the present invention provides a mutans streptococcus inhibitor, wherein the active ingredient of the inhibitor includes the above-mentioned polypeptide with anti-caries performance and / or a polypeptide self-assembled hydrogel with anti-caries performance.

[0016] Based on the same inventive concept, the present invention also provides a method for preparing a polypeptide self-assembled hydrogel with anti-caries performance, the preparation method comprising:

[0017] A polypeptide having an anti-caries property is mixed with a PBS buffer to obtain a reaction solution;

[0018] The reaction solution is reacted at 23-37° C. for a period of time to obtain a polypeptide self-assembled hydrogel with anti-caries performance.

[0019] Preferably, in the reaction solution, the polypeptide concentration is 4-10 mmol / L, and the phosphate concentration is 6-10 mmol / L;

[0020] The reaction time of the reaction solution is 5 to 30 minutes.

[0021] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0022] 1. A polypeptide with anti-caries performance of the present invention, named A3, has excellent antibacterial activity against a variety of pathogens, especially Streptococcus mutans. The minimum growth inhibition concentration of polypeptide A3 against Streptococcus mutans is significantly lower than that against Escherichia coli and Staphylococcus aureus. Polypeptide A3 can also prepare polypeptide hydrogel by self-assembly to achieve adhesion and sustained release at the carious site of teeth, and can be used as an effective ingredient of anti-caries drugs, providing a new option for the prevention and treatment of early caries in clinical practice.

[0023] 2. The present invention discloses a polypeptide self-assembled hydrogel with anti-caries performance. The polypeptide A3 is used as a raw material. The polypeptide A3 is self-assembled in a PBS solution to form a polypeptide hydrogel. The obtained material not only maintains the original antibacterial properties of the antimicrobial peptide A3, but also has excellent biocompatibility. At the same time, it can also achieve adhesion and sustained release in the carious parts of teeth. The stability of the polypeptide self-assembled hydrogel in different pH environments is studied, and it is found that its in vitro degradation rate slows down with the decrease of pH, which is conducive to the slow release of drugs in an acidic caries environment and has important significance for the inhibition of early caries in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0025] Figure 1 The minimum bactericidal concentration of compound A3 against standard bacterial strains of Streptococcus mutans was determined.

[0026] Figure 2 This graph shows the effect of compound A3 on the proliferation of cell line L929.

[0027] Figure 3 The preparation process of antimicrobial peptide self-assembled hydrogel (vial inversion experiment).

[0028] Figure 4 Antimicrobial activity of antimicrobial peptide self-assembled hydrogel.

[0029] Figure 5 This is the growth of the colony after the action of antimicrobial peptide self-assembled hydrogel.

[0030] Figure 6 These are the experimental results of antimicrobial peptide self-assembled hydrogel CCK-8.

[0031] Figure 7 These are the experimental results of LDH release from antimicrobial peptide self-assembled hydrogels.

[0032] Figure 8 Live / dead cell staining results of antimicrobial peptide self-assembled hydrogels. DETAILED DESCRIPTION

[0033] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0034] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0035] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0036] The overall idea of ​​the present invention is as follows:

[0037] Traditional antimicrobial peptides not only control the growth of Streptococcus mutans, but also have the same inhibitory effect on other commensal bacteria, which greatly affects the balance of oral flora and has an extremely adverse effect on oral health. In addition, dental caries mainly occur in the crown area, and due to the characteristics of blood vessel distribution, systemic medication is difficult to reach. Local application is a relatively effective way of drug delivery, but most drugs need to be attached to and released slowly in the tooth area under certain conditions of drug carrier assistance.

[0038] Hydrogels are highly hydrophilic three-dimensional network gels that can swell rapidly in water but cannot dissolve. Hydrogels can absorb large amounts of water while maintaining their original structure after swelling. As a soft substance, hydrogels are widely used in the biomedical field. Compared with traditional synthetic hydrogels, peptide self-assembled hydrogels have many advantages. Similar to other molecular self-assembly systems, the self-assembly of peptides depends on the interaction of non-covalent bonds. First, the structure and function of hydrogels can be adjusted by adjusting the structure of peptides. Second, peptide hydrogels have stable mechanical properties, porous structures, and good biocompatibility, which are beneficial to the migration and growth of the cells they carry. Finally, the large specific surface area of ​​peptides can promote the adsorption of drugs and biomolecules.

[0039] Based on this, the present invention provides a polypeptide with anti-caries performance. The present invention captures the antibacterial characteristics of antimicrobial peptides by computer, learns these characteristics by artificial intelligence, establishes a prediction model, and screens out a polypeptide with high antibacterial activity from a series of generated non-natural antimicrobial peptides, whose amino acid sequence is RRRWRWRIGI RIY, and is marked as compound A3.

[0040] The experiment found that compound A3 has excellent antibacterial activity against a variety of pathogens, especially Streptococcus mutans. The minimum growth inhibition concentration of peptide A3 against Streptococcus mutans is significantly lower than that against Escherichia coli and Staphylococcus aureus. In addition, compound A3 can self-assemble into peptide hydrogel in PBS solution. This material not only maintains the original antibacterial properties of antimicrobial peptides, but also has excellent biocompatibility, and can also achieve adhesion and sustained release in the carious parts of teeth. The stability of peptide hydrogel in different pH environments was studied, showing that its in vitro degradation rate slowed down with decreasing pH, which is conducive to the slow release of drugs in acidic caries environments, providing a new idea for the inhibition of early caries in clinical practice.

[0041] The following is a detailed description of a polypeptide and a polypeptide self-assembled hydrogel with anti-caries performance in the present application in combination with examples and experimental data.

[0042] Example 1

[0043] This example describes the synthesis and purification of a polypeptide having anti-caries properties.

[0044] The synthesis of the peptide (i.e., compound A3) adopts the classical peptide solid phase synthesis method, and the specific steps are as follows:

[0045] 1) Swelling resin: Weigh a certain amount of resin and add it to the peptide synthesizer, then add an appropriate amount of redistilled DCM and stir for 30 minutes to make the resin swell completely. After drying, wash the resin with redistilled DMF 4 times, 3 minutes each time, and drain.

[0046] 2) Indene test: Take a small amount of resin and place it in a test tube. Add indene test reagent (ninhydrin: pyridine: phenol = 1:2:1) and heat in boiling water for 3 minutes. If the color of the resin does not change, proceed to the next step.

[0047] 3) Deprotection: Add deprotection reagent (piperidine:DMF=1:4) to the synthesizer, stir, repeat 3 times, 5 minutes each time, to completely remove the Fmoc protecting group, wash the resin 4 times with redistilled DMF, 3 minutes each time. Check again, if the resin is blue-purple, it proves that the deprotection is successful.

[0048] 4) Condensation reaction: Weigh 3 times excess of Fmoc-protected amino acid and condensation agents HOBT and HBTU, dissolve in redistilled DMF, add 6 times excess of initiator DI EA, stir and mix, add to synthesizer, stir for 1 hour under inert gas protection, drain, wash the resin 4 times with redistilled DMF, 3 minutes each time, drain, check, if the color of the resin does not change, it proves that the condensation reaction is successful. Repeat the steps of removing Fmoc protecting group and condensation reaction until the whole peptide chain is fully synthesized.

[0049] 5) Peptide cleavage: After the last amino acid is condensed, remove the Fmoc protecting group, wash the resin with redistilled DMF 4 times, 3 min each time, then wash the resin with DCM and anhydrous methanol alternately 3 times, 3 min each time, and place the resin in a vacuum drying oven. After the resin is completely dry, add the cleavage reagent (TFA: Ti s: H2O = 95:2.5:2.5), stir slowly for 3 hours, and collect the cleavage solution.

[0050] 6) Extraction of polypeptides: The cutting solution was decompressed and dried by spin drying, and stored in a -20°C refrigerator for 15 min. After being taken out, an appropriate amount of ice ether was added for precipitation, and the solution was extracted with water. The aqueous phase was collected in a beaker and freeze-dried to obtain a crude peptide powder.

[0051] 7) Purification of polypeptides: Purify the polypeptides using reversed-phase high performance liquid chromatography, dissolve the crude peptide powder, filter and load the sample, the elution system is 15%-95% acetonitrile in water, the flow rate is 10mL / min, elution is 80min, observe the changes in the peak shape of the spectrum at 220nm and 254nm, collect the eluate at the main peak and mark it, and freeze-dry to obtain pure peptides. Perform purity analysis using reversed-phase high performance liquid chromatography, take a small amount of pure peptide, dissolve, load the sample, the elution system is 5%-95% acetonitrile in water, the flow rate is 1mL / min, elution is 30min, the spectrum is integrated, the purity is calculated, and the actual molecular weight of the polypeptide is detected by mass spectrometry.

[0052] The amino acid sequence of the obtained compound A3 is shown in Table 1.

[0053] Table 1 Amino acid sequences and theoretical molecular weights of synthesized compounds

[0054] Compound Amino acid sequence Theoretical molecular weight A3 RRRWRWRIGIRIY 1887.24

[0055] Example 2

[0056] In this example, the minimum inhibitory concentration of compound A3 was determined.

[0057] The standard strains used for the determination of the antibacterial activity of the compounds: Streptococcus mutans (ATCC 25175), Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), Escherichia coli (ATCC 25922), and Streptococcus pneumoniae (ATCC49619) were all from the American Type Culture Collection.

[0058] The minimum inhibitory concentration (MIC) values ​​of the compounds against bacteria were slightly modified according to the Clinical and Laboratory Standards Institute (CLSI) microdilution method. In brief, a single bacterial colony was picked up in 4 ml of the corresponding culture medium, incubated on a shaker at 37 °C and 180 rpm for 18 h, and the bacterial solution was diluted to 1 × 10 5The minimum inhibitory concentration of the compound against the selected strain was tested by the microbroth dilution method: the compound solution of different concentrations after multiple dilution was added to a sterile 96-well plate, and the final concentration of the bacterial solution in each well was 1×10 4 CFU / ml. First, add 100μl of BHI medium to each well, dilute the 2mg / ml drug solution to 512μM, add 100μl of drug solution to each well of wells 1-5 in the first row A to make the concentration 256μM, and dilute to 128μM, 64μM, 32μM, 16μM, 8μM, 4μM, 2μM in the gradient to the concentrations of BH wells, respectively, and add 100μl of BHI medium to each well to make the system 200μl, and add 20μl of bacterial solution with a concentration of 1×105CFU / ml to each well to ensure that the final concentration of the bacterial solution in each well is 1×10 4 CFU / ml. The culture conditions corresponding to each strain were cultured for 24 h, and the lowest concentration at which no bacteria grew in the wells at OD 600 nm was determined as MIC. The above experiment was effectively repeated 3 times. The experimental results are shown in Table 2.

[0059] Table 2 Minimum inhibitory concentration of compound A3 against standard bacterial strains

[0060]

[0061] It can be seen from Table 2 that compound A3 exhibited good antibacterial activity against all the tested bacteria.

[0062] Example 3

[0063] This example conducts a minimum bactericidal concentration test of compound A3:

[0064] In the above MIC determination experiment, 50 μl of mutans streptococcus liquid was taken out from the small hole and evenly coated on a suitable agar solid culture medium. The plate was inverted and cultured for 24 hours under suitable culture conditions. The lowest concentration at which no colony growth could be observed on the plate was defined as the minimum bactericidal concentration (MBC). The above experiment was effectively repeated 3 times. The experimental results are shown in the figure. Figure 1 shown.

[0065] from Figure 1 It can be seen that at a concentration of 8 MIC, no colony growth can be observed on the plate, which is the MBC concentration.

[0066] Example 4

[0067] In this example, a cytotoxicity experiment of compound A3 was conducted.

[0068] The cytotoxicity of compound A3 was determined by the CCK-8 method to determine the proliferation of mouse epithelial fibroblast L929. The cell lines used in this example were provided by the Experimental Center of Lanzhou University Basic Medical College. L929 cells were cultured in a cell culture incubator at 37°C and 5% CO2 using high-glucose DMEM medium containing 10% fetal bovine serum.

[0069] Detection of the in vitro toxicity of compound A3 on L929 cells:

[0070] The cell suspension was seeded in a 96-well plate (8 × 10 cells per well). 3 ), add 100μl high-glucose DMEM culture medium containing 10% fetal bovine serum to each well, and culture in an incubator. After the cells adhere to the wall, aspirate and discard the old culture medium, use complete culture medium to gradiently dilute the compound, add 100μl diluted compound solution to each well, set up 3 replicate wells for each group, and use a control group without compound addition. Place the culture plate in an incubator and culture for 24h, 48h, and 72h, then discard the original culture medium, add 10μ1cck-8 solution and 100μl complete culture medium, shake the culture plate gently, and continue to culture in the incubator for 1-2h. Detect the absorbance at a wavelength of 450nm, and finally calculate the cytotoxicity *(%) = [A(drug added)-A(blank)] / [A(0 drug added)-A(blank)]×100%. The experimental results are as follows Figure 2 shown.

[0071] from Figure 2 It can be seen that after the antimicrobial peptide A3 acts on L929 cells, at the minimum inhibitory concentration (8 μM), the cell survival rate is close to 80%, and the cell compatibility is good.

[0072] Example 5

[0073] This example describes the preparation of a polypeptide self-assembled hydrogel with anti-caries properties.

[0074] In order to explore the effects of antimicrobial peptide A3 concentration and PBS concentration on hydrogel formation, the controlled variable method was adopted, and the vial inversion observation was performed to explore the effects of the above factors on the formation of antimicrobial peptide self-assembled hydrogel.

[0075] A certain amount of antimicrobial peptide A3 was dissolved in sterile water to prepare a 25mM storage solution, and then the A3 storage solution was added to different concentrations of PBS (0mM, 2mM, 4mM, 6mM, 8mM, 10mM) at pH 7.4 to prepare a reaction solution with a final concentration of 5mM or 10mM. The reaction was carried out at 23°C for 5 minutes, and the fluidity of the solution was observed. The antimicrobial peptide A3 storage solution was then added to 8mM PBS at pH 7.4 at different final concentrations (0mM, 0.5mM, 1mM, 2mM, 3mM, 4mM, 5mM, 10mM) at 23°C for 5 minutes, and the fluidity of the solution was observed. The results are as follows: Figure 3 shown.

[0076] from Figure 3 It can be seen that when the PBS concentration is 6mM, the A3 concentration is 5mM or 10mM, peptide self-assembled hydrogels can be formed. However, when the A3 concentration is 10mM, the hydrogel morphology is unstable due to insufficient PBS ion concentration. When the PBS concentration is 8mM, the A3 concentration is 5mM or 10mM, stable peptide self-assembled hydrogels can be formed. When the PBS concentration is controlled to be 8mM, as the concentration of antimicrobial peptide A3 gradually increases, the fluidity and transparency of the entire system gradually decrease. When A3 is 5mM, a stable peptide self-assembled hydrogel can be formed. Finally, we selected the peptide self-assembled hydrogel formed by A3 concentration of 5mM and PBS concentration of 8mM for subsequent experiments.

[0077] Example 6

[0078] This example tests the antibacterial activity of the antimicrobial peptide self-assembled hydrogel.

[0079] Streptococcus mutans (S. mutans) was used to detect the antibacterial activity of A3 self-assembled hydrogel (A3 concentration of 5mM, PBS concentration of 8mM):

[0080] Pick a single colony from the BHI agar plate, inoculate it in 4 ml of BHI liquid medium, and culture it at 37°C in a constant temperature shaker at 180 rpm for 8-12 h until the logarithmic phase. Pipette 700 μl of the antimicrobial peptide self-assembled hydrogel into a 1.5 ml sterile EP tube, use the same volume of PBS as the negative control group, and dilute the bacterial solution in the logarithmic growth phase to 1×10 5 CFU / ml, slowly add 700μl bacterial solution to the hydrogel or PBS, incubate in a 37℃ constant temperature incubator for 0h, 3h, 6h, 9h, 12h, and 24h, gently shake the bacterial solution evenly, take out 100μl bacterial solution and add it to a sterile 96-well plate in turn, set up three sets of parallel control wells, and use a multifunctional microplate reader to detect the light absorption value (OD600) at 600nm. At the same time, take out 100μl bacterial solution and dilute it in BHI medium for 10 6After adding the solution to the BHI agar plate, spread it evenly with a spreader stick and place it in a 37°C constant temperature incubator for incubation. After 18 hours, record the growth of the colonies on the plate. Figure 4 , 5 shown.

[0081] from Figure 4 , 5 It can be seen that the antibacterial activity of A3 self-assembled hydrogel was judged by judging the change of OD600 value of bacterial solution. The OD600 value of bacterial solution in the control group gradually increased, indicating that the activity of bacteria was normal, while the OD600 value of the experimental group did not change with the extension of incubation time, indicating that A3 self-assembled hydrogel can effectively inhibit the proliferation of Streptococcus mutans.

[0082] According to the growth of colonies on the plates, the number of colonies on the control group plates gradually increased, indicating that the bacterial activity was normal. At 3 hours, the bacteria on the hydrogel group plates did not grow, and as time went on, no colonies appeared on the plates, indicating that the A3 self-assembled hydrogel could quickly kill the mutans Streptococcus incubated with it.

[0083] Example 7

[0084] This example tests the cytotoxicity of the antimicrobial peptide self-assembled hydrogel.

[0085] 1. CCK-8 method was used to determine the cytotoxicity of antimicrobial peptide self-assembled hydrogels to L929 cells: L929 cells were cultured at 4×10 4 / ml density in a 96-well plate and incubated in a cell culture incubator for 24h; then discard the supernatant, add DMEM medium (100μl per well) that was previously balanced with the hydrogel and the control group PBS for 24h and fetal bovine serum in the corresponding proportion to continue incubation for 24h, 48h and 72h. After the incubation, discard the supernatant, prepare CKK-8 application solution according to the ratio of CCK-8 solution: complete culture medium = 1:10, add 100μl to each well, and measure OD450nm after culturing for 1.5h to evaluate the cytotoxicity of the antimicrobial peptide self-assembled hydrogel. The results are as follows Figure 6 shown.

[0086] from Figure 6 It can be seen that after L929 cells were co-incubated with A3 self-assembled hydrogel for 24h, 48h, and 72h, there was no significant difference compared with the control group, indicating that A3 self-assembled antimicrobial peptide has good cell compatibility.

[0087] 2. The cytotoxicity of the hydrogel was determined by LDH (lactate dehydrogenase) release experiment: L929 cells were cultured at 4×10 4 / ml density in a 96-well plate and incubated in a cell culture incubator for 24h; then discard the supernatant, add DMEM culture medium (100μl per well) that had been equilibrated with PBS for 24h in advance with the hydrogel and negative control group and the corresponding proportion of fetal bovine serum and continue incubating for 24h, 48h and 72h, use the LDH release reagent in the LDH release kit (C0016-1, Beyotime) as the maximum enzyme activity control (positive control) of the sample, and after the incubation, use Beyotime's LDH release kit to determine the LDH release of all cells. The LDH release of A3 hydrogel was calculated using the following formula: LDH release = (OD490 (hydrogel) - OD490 (blank)) / (OD490 (MAX) - OD490 (blank)), to determine the effect of antimicrobial peptide gelation on its cytotoxicity. The results are shown in Figure 7 shown.

[0088] from Figure 7 It can be seen that the amount of cell death and thus cytotoxicity can be determined by the amount of LDH released. There was no significant difference between the experimental group and the PBS control group at 24h, 48h, and 72h, indicating that the A3 self-assembling antimicrobial peptide has good cell compatibility.

[0089] 3. Live cells / dead cells were dyed green / red by live cell / dead cell staining method, and then the density and state of cells were observed using a fluorescence microscope to determine the cytotoxicity of the antimicrobial peptide self-assembled hydrogel.

[0090] First, L929 cells were cultured at 4 × 10 4 / ml density in a 96-well plate and incubated in a cell culture incubator for 24 hours; then discard the supernatant, add DMEM that has been equilibrated with the hydrogel and control group PBS for 24 hours, and continue to incubate for 24 hours, 48 ​​hours and 72 hours. After the incubation, discard the supernatant, add the corresponding fluorescent dye to stain the cells, and finally observe the cell morphology under a fluorescence microscope and take pictures. Among them, living cells are stained with calcein AM; dead cells are stained with BOBO-3 iodide, and the action time is 15 minutes. The results are as follows Figure 8 shown.

[0091] from Figure 8 It can be seen that after incubation with A3 self-assembled hydrogel, the morphology and proliferation of L929 cells were not affected. All cells in the experimental group showed a complete and healthy adherence state, and with the extension of incubation time, the cell density of the experimental group gradually increased, showing a growth trend comparable to that of the control group, further indicating that A3 self-assembled antimicrobial peptide has good cell compatibility.

[0092] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0093] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0094] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A polypeptide having anti-caries properties, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO.

1.

2. A polypeptide self-assembled hydrogel with anti-caries properties, characterized in that: The polypeptide self-assembly hydrogel contains the polypeptide with anti-caries performance as claimed in claim 1.

3. The polypeptide self-assembled hydrogel with anti-caries performance according to claim 2, characterized in that: The polypeptide self-assembly hydrogel is formed by self-assembly of the polypeptide in a solvent.

4. The polypeptide self-assembled hydrogel with anti-caries performance according to claim 3, characterized in that: The solvent is PBS buffer.

5. Use of the polypeptide with anti-caries property as claimed in claim 1 in the preparation of anti-caries drugs.

6. Use of the polypeptide self-assembled hydrogel with anti-caries properties as claimed in claims 2 to 4 in the preparation of anti-caries drugs.

7. An anti-caries drug, characterized in that: The active ingredient of the anti-caries drug includes the polypeptide with anti-caries performance as claimed in claim 1 and / or the polypeptide self-assembled hydrogel with anti-caries performance as claimed in claims 2 to 4.

8. A mutans streptococcus inhibitor, characterized in that The active ingredient of the inhibitor comprises the polypeptide with anti-caries performance as claimed in claim 1 and / or the polypeptide self-assembled hydrogel with anti-caries performance as claimed in claims 2 to 4.

9. The method for preparing a polypeptide self-assembled hydrogel with anti-caries performance as claimed in claims 2 to 4, characterized in that: The preparation method comprises: A polypeptide having an anti-caries property is mixed with a PBS buffer to obtain a reaction solution; The reaction solution is reacted at 23-37° C. for a period of time to obtain a polypeptide self-assembled hydrogel with anti-caries performance.

10. The method for preparing a polypeptide self-assembled hydrogel with anti-caries performance according to claim 9, characterized in that: In the reaction solution, the polypeptide concentration is 4 to 10 mmol / L, and the phosphate concentration is 6 to 10 mmol / L; The reaction time of the reaction solution is 5 to 30 minutes.

Citation Information

Patent Citations

  • Dual-effect anti-caries polypeptide with functions of resisting to bacteria and promoting remineralization, polypeptide derivative and salt thereof, and application

    AU2020102985A4

  • Double-effect anticariogenic polypeptide, polypeptide derivatives, polypeptide pharmaceutical salts and application

    CN107353351A

  • Streptococcus mutans specific targeting antibacterial peptide and application thereof

    CN112961216A

  • Antibacterial peptide and application thereof

    CN113336826A

  • Antibacterial peptide and application thereof

    CN113717254A